Premium
Real‐world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group
Author(s) -
Akahane Takehiro,
Kurosaki Masayuki,
Itakura Jun,
Tsuji Keiji,
Joko Kouji,
Kimura Hiroyuki,
Nasu Akihiro,
Ogawa Chikara,
Kojima Yuji,
Hasebe Chitomi,
Wada Shuichi,
Uchida Yasushi,
Sohda Tetsuro,
Suzuki Hideyuki,
Yoshida Hideo,
Kusakabe Atsunori,
Tamada Takashi,
Kobashi Haruhiko,
Mitsuda Akeri,
Kondo Masahiko,
Shigeno Masaya,
Ide Yasushi,
Morita Atsuhiro,
Kitamura Tadashi,
Abe Takehiko,
Izumi Namiki
Publication year - 2019
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.13246
Subject(s) - medicine , ribavirin , sofosbuvir , gastroenterology , hepatitis c , adverse effect , odds ratio , incidence (geometry) , hepatitis c virus , population , pegylated interferon , immunology , virus , physics , environmental health , optics
Aim This study aimed to describe the real‐world efficacy and safety of sofosbuvir (SOF) + ribavirin (RBV) for chronic hepatitis C, genotype 2. Methods This was a retrospective analysis of a nationwide, multicenter registry including 914 hepatitis C genotype 2 Japanese patients treated with SOF + RBV for 12 weeks. The rate of sustained virologic response at 12 weeks after treatment (SVR12), incidence of adverse events, and changes in serological parameters were analyzed. Results Treatment was completed in 98.9% of patients. Ribavirin dose reduction was required in 29.7% of patients. The SVR12 rate was 96.8% in the intention‐to‐treat population and 97.6% in the per‐protocol population. Factors associated with SVR12 were absence of advanced fibrosis (odds ratio, 5.76, P = 0.003) and interferon‐treatment‐naïve status (odds ratio, 4.79, P = 0.017). Dose reduction or total adherence of RBV was not associated with SVR. The resistance‐associated substitution S282 T in NS5B was not detected in any patient at virologic failure. Serum albumin levels significantly increased, and the degree of increase was greater in patients with advanced fibrosis than in those without (0.21 ± 0.32 vs . 0.05 ± 0.29, P < 0.0001). Alpha‐fetoprotein decreased significantly at end of treatment ( P < 0.0001), and the degree of decrease was greater in patients with advanced fibrosis than in those without (21.7 ± 60.8 vs . 2.5 ± 15.5, P < 0.001). The most commonly reported adverse event was anemia (13.7%). Conclusions Treatment with SOF + RBV was highly effective and safe in Japanese patients with HCV genotype 2 infection.